<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sbarouni, E</style></author><author><style face="normal" font="default" size="100%">Flevari,P.</style></author><author><style face="normal" font="default" size="100%">Kroupis, C.</style></author><author><style face="normal" font="default" size="100%">Kyriakides, ZS</style></author><author><style face="normal" font="default" size="100%">Koniavitou,K.</style></author><author><style face="normal" font="default" size="100%">Kremastinos, D.T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of raloxifene and simvastatin on plasma lipids and endothelium</style></title><secondary-title><style face="normal" font="default" size="100%">Cardiovasc.Drugs Ther.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Blood</style></keyword><keyword><style  face="normal" font="default" size="100%">blood supply</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell adhesion molecules</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronary artery disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style  face="normal" font="default" size="100%">drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Endothelium,Vascular</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Forearm</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Hypercholesterolemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style  face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">physiopathology</style></keyword><keyword><style  face="normal" font="default" size="100%">POSTMENOPAUSE</style></keyword><keyword><style  face="normal" font="default" size="100%">Raloxifene Hydrochloride</style></keyword><keyword><style  face="normal" font="default" size="100%">Regional Blood Flow</style></keyword><keyword><style  face="normal" font="default" size="100%">Selective Estrogen Receptor Modulators</style></keyword><keyword><style  face="normal" font="default" size="100%">Simvastatin</style></keyword><keyword><style  face="normal" font="default" size="100%">Vascular Resistance</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2003/07//</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">PM:14618093</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">319 - 323</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">PURPOSE: Raloxifene is a selective estrogen receptor modulator and an attractive alternative to estrogen replacement as it obviates the need for a progestin and does not increase C-reactive protein levels. We compared the effects of simvastatin and raloxifene treatments on the lipid profile, the levels of adhesion molecules and the endothelium dependent and independent vasoreactivity. SUBJECTS &amp; METHODS: We treated 12 postmenopausal women with hypercholesterolemia and coronary artery disease with raloxifene 60 mg/day and simvastatin 20 mg/day in a randomized, double-blind, crossover study. Each treatment period was 8 weeks long with a 4-week washout interval. Plasma lipids and cellular adhesion molecules were evaluated and peripheral blood flow studies with venous occlusion plethysmography were performed. RESULTS: Both simvastatin and raloxifene significantly reduced total [33% (27-40), 12% (0-24)] and LDL [44% (36-52), 16% (0-33)] cholesterol compared to baseline values (p &lt; 0.05) but simvastatin was more effective than raloxifene (p &lt; 0.005). None of the treatments had any significant effect on HDL cholesterol and triglyceride levels. Only raloxifene significantly reduced Lp(a) [18% (1-36)] and ICAM-1 [17% (8-25)] and VCAM-1 [24% (15-33)] plasma levels compared to baseline (p = 0.019, p &lt; 0.0001 and p = 0.003, respectively). Hyperemic blood flow response on raloxifene was significantly higher compared to baseline [52% (0-105)], (p &lt; 0.05), whereas no significant change was noted on simvastatin. Endothelium independent blood flow induced by nitroglycerine was not influenced by either active treatment. CONCLUSIONS: Raloxifene administration is associated with lower ICAM-1, VCAM-1 and Lp(a) plasma levels and enhanced endothelium dependent dilation compared to simvastatin although simvastatin is more powerful in total and LDL cholesterol reduction</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">DA - 20031117IS - 0920-3206 (Print)IS - 0920-3206 (Linking)LA - engPT - Clinical TrialPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Cell Adhesion Molecules)RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)RN - 0 (Lipids)RN - 0 (Selective Estrogen Receptor Modulators)RN - 4F86W47BR6 (Raloxifene Hydrochloride)RN - AGG2FN16EV (Simvastatin)SB - IM</style></notes></record></records></xml>